Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does SECUKINUMAB Cause Disturbance in attention? 88 Reports in FDA Database

Visibly Younger Skin in Weeks

Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.

Discover Synevra

According to the FDA Adverse Event Reporting System (FAERS), 88 reports of Disturbance in attention have been filed in association with SECUKINUMAB (COSENTYX). This represents 0.1% of all adverse event reports for SECUKINUMAB.

88
Reports of Disturbance in attention with SECUKINUMAB
0.1%
of all SECUKINUMAB reports
1
Deaths
33
Hospitalizations

How Dangerous Is Disturbance in attention From SECUKINUMAB?

Of the 88 reports, 1 (1.1%) resulted in death, 33 (37.5%) required hospitalization, and 9 (10.2%) were considered life-threatening.

Is Disturbance in attention Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for SECUKINUMAB. However, 88 reports have been filed with the FAERS database.

What Other Side Effects Does SECUKINUMAB Cause?

Drug ineffective (27,434) Psoriasis (21,976) Pain (15,244) Arthralgia (13,769) Fatigue (9,406) Psoriatic arthropathy (8,900) Pruritus (8,755) Malaise (8,570) Rash (8,023) Condition aggravated (7,536)

What Other Drugs Cause Disturbance in attention?

LEVOTHYROXINE (1,718) METHYLPHENIDATE (1,414) AMPHETAMINE ASPARTATE\AMPHETAMINE\DEXTROAMPHETAMINE SACCHARATE\DEXTROAMPHETAMINE (1,321) DULOXETINE (986) PREGABALIN (950) LISDEXAMFETAMINE DIMESYLATE (911) OXYCODONE (829) QUETIAPINE (747) ACETAMINOPHEN\HYDROCODONE (746) ACETAMINOPHEN\OXYCODONE (734)

Which SECUKINUMAB Alternatives Have Lower Disturbance in attention Risk?

SECUKINUMAB vs SELADELPAR LYSINE SECUKINUMAB vs SELEGILINE SECUKINUMAB vs SELENIUM SECUKINUMAB vs SELENIUM SULFIDE SECUKINUMAB vs SELEXIPAG

Related Pages

SECUKINUMAB Full Profile All Disturbance in attention Reports All Drugs Causing Disturbance in attention SECUKINUMAB Demographics